Boston Scientific Corp to Discuss LOTUS Edge™ Aortic Valve System Voluntary Recall and Product Discontinuation - Conference Call Transcript
Good day and welcome to the Boston Scientific Investor Update. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to Susan Lisa, Vice President, Investor Relations. Please go ahead.
Thank you, Andrew. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; Dan Brennan, Executive Vice President and Chief Financial Officer; Dr. Ian Meredith, Global Chief Medical Officer; and Joe Fitzgerald, Executive President -- Executive Vice President and President, Interventional Cardiology.
We issued a press release earlier this morning announcing the voluntary recall and product discontinuation of the LOTUS Edge aortic valve system and will spend the duration of this morning's call discussing our decision.
Before we begin, I'd like to remind everyone that on the call, operational revenue excludes the impact of foreign currency fluctuations, and organic revenue
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |